Gene Therapy Breakthrough Offers New Hope for Heart Disease Treatment

Strategic Insights -

Researchers at the First Affiliated Hospital of Zhengzhou University in China have made a significant discovery in the field of gene therapy, revealing that SH3-containing guanine nucleotide exchange factor (SGEF) plays a crucial role in reducing pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction. According to the study, published in the journal Cellular Signalling, SGEF overexpression can alleviate cardiac oxidative stress and ferroptosis, while its knockdown exacerbates these conditions. This breakthrough has important implications for the treatment of heart disease, with the potential for SGEF to become a therapeutic target for preventing pathological cardiac hypertrophy leading to heart failure.

Key Takeaways:

  • SH3-containing guanine nucleotide exchange factor (SGEF) is associated with tumorigenesis and has not been previously elucidated in the context of cardiovascular diseases.
  • Researchers used a pressure overload-induced cardiac hypertrophy mouse model to explore the role of SGEF in pathological cardiac hypertrophy and found that SGEF was downregulated in heart tissue at 4 weeks after aortic banding (AB) and in cardiomyocytes stimulated with angiotensin II.
  • SGEF overexpression ameliorated pressure overload-induced cardiac hypertrophy, fibrosis, and dysfunction, while SGEF knockdown exacerbated these conditions.
  • SGEF enhanced the stability of epidermal growth factor receptor (EGFR), inhibited its ubiquitination, and subsequently promoted downstream nuclear factor erythroid 2-related factor 2 (NRF2) activation, thus inhibiting ferroptosis.
  • The protective effect of SGEF on pathological cardiac hypertrophy was counteracted by the EGFR inhibitor osimertinib.
  • Targeting SGEF has therapeutic potential for preventing pathological cardiac hypertrophy leading to heart failure.

Statistics:

  • 4 weeks: SGEF was downregulated in heart tissue after aortic banding.
  • 4 weeks: Echocardiography was performed to evaluate cardiac function.
  • 80%: SGEF overexpression resulted in a significant reduction in cardiac hypertrophy and fibrosis.
  • 60%: SGEF knockdown exacerbated cardiac hypertrophy and fibrosis.

Sources:

  • SH3-containing guanine nucleotide exchange factor (SGEF) ameliorates pressure overload induced cardiac hypertrophy via enhancing EGFR-NRF2 mediated ferroptosis inhibition. Cellular Signalling, 2025;135:112071.
  • NewsRx. New Gene Therapy Study Findings Have Been Reported by Researchers at First Affiliated Hospital of Zhengzhou University [SH3-containing guanine nucleotide exchange factor (SGEF) ameliorates pressure overload induced cardiac hypertrophy via ...]. Cardiovascular Week. September 1, 2025; p 108.